AccuMedical nets over RMB100m in Series B round led by Sequoia Capital China

On July 13, AccuMedical has garnered more than 100 million yuan in its Series B round of financing, led by Sequoia Capital China and joined by Huagai Capital.
Previously, the company secured its Series A round from BioTrack Capital and Proxima Ventures Capital, among others.

On July 13, AccuMedical has garnered more than 100 million yuan in its Series B round of financing, led by Sequoia Capital China and joined by Huagai Capital.

Previously, the company secured its Series A round from BioTrack Capital and Proxima Ventures Capital, among others.

Founded in 2016, AccuMedical is headquartered in Beijing, China, with a research and development center in California, US.

The company hosts a full product line in the field of neurointerventional medicine, develops and manufactures medical device products for the treatment of cerebral aneurysms. Currently, AccuMedical has completed innovative designs of several products.

As far as the Chinese market is concerned, the new era of domestic devices should not just be simple imitation of imported products, according to the founder of AccuMedical. The company intends to make the most of its advantages and deliver the world’s most advanced neuro-interventional devices to the doctors in China.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/15/accumedical-nets-over-rmb100m-in-series-b-round-led-by-sequoia-capital-china/.

Leave a Reply

Please Login to Comment